Authors: BLANKE CD KASIMIS B SCHEIN P CAPIZZI R KURMAN M

Citation: Cd. Blanke et al., PHASE-II STUDY OF TRIMETREXATE, FLUOROURACIL, AND LEUCOVORIN FOR ADVANCED COLORECTAL-CANCER, Journal of clinical oncology, 15(3), 1997, pp. 915-920

Authors: BLANKE C KASIMIS B SCHEIN P

Citation: C. Blanke et al., TRIMETREXATE (TMTX) MODULATION OF 5-FLUOROURACIL LEUCOVORIN (5-FU LV)FOR ADVANCED COLORECTAL-CANCER/, European journal of cancer, 31A, 1995, pp. 748-748

Authors: OSTER W SCHEFFLER B CAPIZZI R SCHEIN P

Citation: W. Oster et al., AMIFOSTINE - PROTECTION FROM HEMATOTOXICITY AND NEPHROTOXICITY INDUCED BY CHEMOTHERAPY, European journal of cancer, 31A, 1995, pp. 83-83

Authors: OSTER W HABBOUBI N SCHEFFLER B CAPIZZI R SCHEIN P

Citation: W. Oster et al., AMIFOSTINE - A NEWLY DEVELOPED ENTITY FOR CHEMOPROTECTION (PROTECTIONFROM HEMATO, NEPHROTOXICITY, OTOTOXICITY AND NEUROTOXICITY), Experimental hematology, 23(8), 1995, pp. 843-843

Authors: POPLIN EA LORUSSO P LOKICH JJ GULLO JJ LEMING PD SCHULZ JJ VEACH SR MCCULLOCH W BAKER L SCHEIN P

Citation: Ea. Poplin et al., RANDOMIZED CLINICAL-TRIAL OF MITOMYCIN-C WITH OR WITHOUT PRETREATMENTWITH WR-2721 IN PATIENTS WITH ADVANCED COLORECTAL-CANCER, Cancer chemotherapy and pharmacology, 33(5), 1994, pp. 415-419

Authors: GREEN D BENSELY D SCHEIN P

Citation: D. Green et al., PRECLINICAL EVALUATION OF WR-151327 - AN ORALLY-ACTIVE CHEMOTHERAPY PROTECTOR, Cancer research, 54(3), 1994, pp. 738-741